Last Updated: April 14, 2026
Selank vs Semax is one of the most common comparisons in nootropic peptide research. Both compounds emerged from the same Russian research lineage at the Institute of Molecular Genetics in Moscow, and both are short synthetic peptides derived from endogenous parent molecules. Yet despite their shared heritage, Selank and Semax target fundamentally different neurochemical pathways. Selank is a Tuftsin analog investigated primarily in anxiety models and immunomodulation studies, while Semax is an ACTH(4-10) fragment studied for its effects on BDNF, NGF, and cognitive enhancement in preclinical research. This guide compares their parent molecules, mechanisms, published research protocols, and how investigators choose between them when designing laboratory experiments. All discussion here is limited to preclinical research findings — these compounds are intended exclusively for laboratory use.
Quick Comparison: Selank vs Semax
| Feature | Selank | Semax |
|---|---|---|
| Parent molecule | Tuftsin (immunopeptide fragment of IgG) | ACTH(4-10) (adrenocorticotropic hormone fragment) |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Primary pathway (preclinical) | GABAergic modulation, immunomodulation, enkephalin stabilization | BDNF and NGF upregulation, melanocortin signaling |
| Secondary effects observed | Serotonergic tone, reduced anxiety-like behavior in rodents | Cognitive performance markers, neurogenic activity |
| HPA axis activation | None reported in published studies | None reported — ACTH(4-10) lacks steroidogenic activity |
| N-Acetyl modification | N-Acetyl-Selank (extends half-life) | N-Acetyl-Semax (extends half-life) |
| Common research form | Lyophilized powder, reconstituted for research | Lyophilized powder, reconstituted for research |
What Are Nootropic Peptides?
Nootropic peptides are short chains of amino acids investigated in preclinical research for their effects on cognition, memory, attention, and neurochemical signaling. Unlike small-molecule nootropics, peptide nootropics are typically derived from — or designed to mimic — endogenous regulatory peptides the body already produces. The Russian research tradition, beginning in the 1980s at the Institute of Molecular Genetics under Nikolai Myasoedov, pioneered a class of “regulatory peptide” nootropics built by isolating the biologically active fragment of a larger parent molecule and then stabilizing it with proline-glycine-proline (Pro-Gly-Pro) extensions to resist enzymatic degradation.
Selank and Semax are the two most widely studied compounds from this lineage. Both retain the functional core of their parent peptides while removing domains responsible for unwanted systemic activity — for example, Semax excludes the steroidogenic portion of ACTH, and Selank extends Tuftsin’s short half-life. For an overview of the broader class, see the nootropic peptides guide.
How Does Selank Work?
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of Tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) naturally cleaved from the Fc region of immunoglobulin G. Native Tuftsin has a plasma half-life of only a few minutes because of rapid peptidase cleavage. Selank appends a Pro-Gly-Pro tripeptide to the C-terminus, dramatically improving stability in research preparations.
In preclinical research, Selank has been investigated for anxiolytic-like activity without the sedation or motor impairment characteristic of benzodiazepine-class compounds. Published studies suggest its effects involve modulation of the GABAergic system, stabilization of endogenous enkephalins by inhibiting their enzymatic degradation, and shifts in expression of genes tied to monoamine metabolism. Rodent studies have also reported immunomodulatory effects consistent with its Tuftsin origin, including changes in cytokine expression patterns and interferon levels in animal models.
One distinguishing feature noted in preclinical literature is that Selank’s anxiolytic-like effect profile in rodents does not appear to produce the tolerance, dependence, or withdrawal-like behaviors commonly associated with direct GABA-A receptor agonists in extended-administration studies. Instead, the evidence supports an indirect modulatory mechanism — Selank appears to influence GABAergic tone through upstream gene-expression changes and enkephalin dynamics rather than by acting as a classical GABA receptor ligand. Researchers studying anxiety-like behavior models, immune-behavior interactions, serotonergic gene expression, or enkephalin dynamics typically select Selank for these investigations. Product details for laboratory use are available on the Selank 5mg page.
How Does Semax Work?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide corresponding to the ACTH(4-10) fragment with a Pro-Gly-Pro C-terminal extension. The parent ACTH molecule is a 39-amino-acid hormone best known for stimulating cortisol release via the adrenal cortex. Critically, the steroidogenic activity of ACTH is localized outside the 4-10 fragment, which means Semax retains the neurotropic properties of ACTH without activating the HPA axis in published animal studies.
Preclinical research indicates that Semax upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, particularly in the hippocampus and basal forebrain of rodent models. Additional studies suggest melanocortin receptor signaling and dopaminergic modulation contribute to observed cognitive performance markers in maze and memory paradigms. Published research also reports neuroprotective effects in cerebral ischemia models, where Semax administration has been associated with reduced infarct volume and improved behavioral recovery scores in animal subjects.
The breadth of transcriptomic changes reported after Semax administration in rat brain tissue is notable. Preclinical research indicates that Semax influences genes tied to vascular remodeling, synaptic plasticity markers, inflammatory cytokines, and oxidative-stress response pathways, in addition to the headline BDNF and NGF effects. This multi-pathway signature is consistent with Semax’s derivation from ACTH, a regulatory hormone with multiple downstream targets. Researchers investigating memory consolidation, neurotrophic factor expression, melanocortin signaling, or neuroprotection protocols in animals commonly select Semax. Product details for laboratory use are available on the Semax 10mg page.
How Do They Compare in Published Research?
The published literature on Selank and Semax diverges along predictable lines that reflect their different parent molecules. Selank research has accumulated primarily in anxiety-like behavior paradigms (elevated plus maze, open field, light/dark box) and immunomodulation assays measuring cytokine expression, interferon levels, and enkephalinase activity. Semax research has concentrated on cognitive performance paradigms (Morris water maze, passive avoidance, radial arm maze), neurotrophic factor expression (BDNF, NGF, TrkB signaling cascades), and cerebral ischemia models measuring infarct volume and neurological deficit scores in rodents.
Representative PubMed-indexed studies for Selank include investigations by Kozlovskaya and colleagues (PMID: 11505544) examining anxiolytic-like activity in rodent conflict-behavior models, and Volkova et al. (PMID: 27568327) on Selank’s influence on enkephalin-degrading enzymes. Additional Selank work has examined effects on gene expression profiles in the rat hippocampus and frontal cortex, with observed changes in transcripts tied to serotonergic signaling and inflammation response pathways. Preclinical research indicates Selank shifts the balance of Th1/Th2 cytokine expression in rodent models, which has been proposed as one mechanism for its anxiolytic-like activity given the documented relationship between inflammatory tone and anxiety-like behavior.
Semax research includes Dolotov et al. (PMID: 16978756) on BDNF and NGF expression changes in rat hippocampus and basal forebrain, Shadrina et al. (PMID: 20186610) on neuroprotective effects in preclinical ischemia models, and Medvedeva et al. (PMID: 23912820) on gene expression profiles following Semax administration in rat brain tissue. The Medvedeva study in particular reported changes across hundreds of transcripts, including genes involved in vascular remodeling, synaptic plasticity, and inflammatory regulation, providing a broad transcriptomic signature that distinguishes Semax from smaller-target nootropics. Shadrina’s ischemia work reported meaningful reductions in rodent infarct volume when Semax was administered within defined post-occlusion windows.
The literature makes clear that these are not interchangeable compounds. A researcher selecting a peptide to probe GABAergic anxiolytic mechanisms would not substitute Semax for Selank, and a researcher studying BDNF upregulation would not substitute Selank for Semax. The pathways studied, behavioral assays used, and downstream biomarkers measured are largely distinct across the two bodies of published work. When both compounds appear in the same manuscript, it is typically in a comparison study designed to demonstrate this dissociation rather than to propose them as substitutes for one another.
Which Should Researchers Choose?
The choice between Selank and Semax depends entirely on the research question being investigated. Both compounds are supplied as lyophilized powder that investigators reconstitute for laboratory use.
Choose Selank when the research protocol targets:
- Anxiety-like behavior models (elevated plus maze, light/dark box, conflict paradigms)
- GABAergic system modulation without benzodiazepine-class confounds
- Enkephalin stabilization or enkephalinase inhibition studies
- Immunomodulation research building on the Tuftsin lineage
- Serotonergic tone and monoamine metabolism gene expression
Choose Semax when the research protocol targets:
- Memory and cognitive performance paradigms (maze learning, passive avoidance)
- BDNF and NGF expression measurement in rodent brain tissue
- Melanocortin receptor signaling experiments
- Neuroprotection and preclinical cerebral ischemia models
- Dopaminergic modulation without HPA axis activation
Some research programs use both compounds in parallel to contrast anxiolytic-pathway effects against neurotrophic-pathway effects within the same animal cohort. When published studies report combined protocols, they typically justify the pairing by the independence of the underlying mechanisms — Selank and Semax do not appear to share a common receptor family, which makes them useful probes for dissociable behavioral outcomes.
Frequently Asked Questions
What does the “N-Acetyl” modification do to Selank and Semax?
The N-Acetyl modification refers to the addition of an acetyl group (CH3CO-) to the N-terminus (the starting amino acid) of the peptide. In preclinical research, this modification primarily extends the compound’s half-life in solution and in biological systems by blocking aminopeptidase enzymes that would otherwise cleave the peptide from its N-terminal end. Published studies suggest N-Acetyl-Selank and N-Acetyl-Semax retain the same pharmacological profile as their parent peptides but with meaningfully longer duration of measurable effect in research preparations. Investigators designing protocols where dosing frequency or stability is a variable sometimes choose the N-Acetyl forms to reduce protocol complexity. These modifications are intended strictly for laboratory research applications.
Why don’t Selank and Semax activate the HPA axis like their parent molecules?
The parent molecule of Semax is ACTH, a 39-amino-acid hormone that stimulates cortisol release through the adrenal cortex. The steroidogenic activity of ACTH, however, depends on amino acid residues outside the 4-10 fragment. By isolating only residues 4-10 and adding a stabilizing Pro-Gly-Pro extension, Semax retains the neurotropic and melanocortin-adjacent activity of ACTH without the portion responsible for HPA axis activation in preclinical research models. Selank’s parent Tuftsin is not an HPA-axis hormone to begin with — it is an immunopeptide, so HPA activation is not a mechanism associated with Tuftsin or its Selank analog in published studies.
Are Selank and Semax delivered orally or intranasally in published research protocols?
In published preclinical literature, Selank and Semax are most frequently administered intranasally to rodent subjects. Intranasal delivery allows the peptides to reach the central nervous system with reduced first-pass degradation compared to oral routes, which is particularly relevant for short peptides that would be rapidly hydrolyzed by gastric and intestinal peptidases. Some research protocols also use intraperitoneal or subcutaneous administration in rodent models when pharmacokinetic comparisons are the study focus. All route-of-administration decisions in the published literature are laboratory-animal protocols. These compounds are supplied as research materials for laboratory use and are not intended for human or animal consumption.
Can Selank and Semax be studied in the same protocol?
Yes. Because Selank and Semax appear to act on distinct neurochemical pathways — GABAergic and enkephalinergic for Selank, BDNF/NGF and melanocortin for Semax — researchers sometimes include both compounds in a single study design to dissociate anxiolytic-type effects from cognitive-type effects within the same animal cohort. Published studies combining the two typically separate administration windows to avoid confounding pharmacokinetic overlap. The mechanistic independence of the two compounds is what makes them attractive as paired probes in preclinical research rather than redundant options.
How are Selank and Semax stored for research use?
Lyophilized Selank and Semax are typically stored at refrigerator temperatures (2-8 degrees C) before reconstitution, and many research protocols recommend long-term storage at -20 degrees C for extended shelf stability. Once reconstituted in bacteriostatic water or saline for research, published protocols suggest keeping the solution refrigerated and using it within a limited window, as peptide integrity in solution degrades faster than in the lyophilized powder form. Investigators working with the N-Acetyl variants generally report slightly improved solution stability, though storage recommendations remain similar. All handling procedures described here are for laboratory research only.
What distinguishes Selank and Semax from small-molecule nootropics?
Small-molecule nootropics — such as racetam-class compounds — generally cross the blood-brain barrier readily, can be administered orally, and typically interact with well-characterized single receptor systems. Peptide nootropics such as Selank and Semax, by contrast, are fragile in gastric environments, often require parenteral or intranasal delivery in research, and tend to engage multiple pathways simultaneously — for example, Semax’s combined BDNF, NGF, and melanocortin effects. This multi-target profile is a consequence of being derived from regulatory peptides that naturally interact with multiple downstream systems. For researchers, this means peptide nootropics tend to produce broader, harder-to-isolate biomarker changes than single-receptor small molecules in preclinical studies.
Related reading: Complete Guide to Nootropic Peptides — the pillar resource covering Selank, Semax, Cerebrolysin, Dihexa, and the broader regulatory peptide class.
All products are intended for laboratory and research purposes only. Not for human or animal consumption. These statements have not been evaluated by the FDA.